Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
about
Hepatitis C virus infection in nephrology patientsNovel approaches to flavivirus drug discovery.Inhibitors of measles virus.In search of a small-molecule inhibitor for respiratory syncytial virus.Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.Targets of emerging therapies for viral hepatitis B and C.Improving the treatment of hepatitis C infection in the UK.Small molecule and novel treatments for chronic hepatitis C virus infection.Taribavirin in the treatment of hepatitis C.HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.Absorption, metabolism, and excretion of [14C]viramidine in humans.Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
P2860
Q30486664-4FBB8157-EF48-4E06-92AB-5D8E2FF401DDQ34206832-0026BE12-0DEB-4E81-9E2E-C846890AA4F9Q35842266-E0EFF738-C054-4725-A8B8-A521772BEA8DQ35917503-86BBE839-8CD0-4579-8DB3-C2E122AF29CEQ36146443-3A33427F-8FF2-477E-986C-F4E2359D4A38Q36382719-E7712809-E2CA-4FA7-8E83-BBDF6C714228Q36653655-B4337095-09E7-48F9-B49B-3D56BF798661Q36719683-0727CC08-A12C-4546-8249-86D461CF451BQ36872859-89D68B24-D404-4BD5-BB42-177B4BD42B8EQ37919889-508DF407-0F47-469D-941B-5E689093F9C3Q40931542-5E7A30A4-23BB-453D-89CE-69FC21E60798Q41473464-86BA836D-E4AA-4C21-8D30-C8518B8E2788Q43851096-D7162326-A808-48BC-82B6-EB6BA0481D98Q45935774-B0B47866-6BCF-4125-AEFF-92B361CCFF1AQ46391838-5125C579-43EB-4DEF-8BFD-8B5BB53E4431Q50100106-396A030D-AE66-4CAA-86BB-72D672FA88E5Q50579684-9D8BFEE8-0B14-4A05-9EE8-2079394BCB9D
P2860
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@en
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@nl
type
label
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@en
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@nl
prefLabel
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@en
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
@en
P2093
Chin-Chung Lin
Christine Xu
Lee Philips
Li-Tain Yeh
P2860
P304
P356
10.1177/0091270004262974
P577
2004-03-01T00:00:00Z